{"transactions":[{"id":951061,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2026-01-05T21:30:29.000Z","date":"2026-01-01","kind":"grant","planned":false,"acquired":true,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service.  The Reporting Person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 52,507 shares underlying deferred restricted stock units."}],"balance_after":115747,"source":{"system":"sec-edgar","filing":"0001294517-26-000002","document":"form4-01052026_040113.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000129451726000002/form4-01052026_040113.xml","form_type":"4"}},{"id":1314438,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.001","published_at":"2025-01-03T21:20:05.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":49383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service.  The reporting person elected to defer 25% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions.  Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Total holdings include 45,676 shares underlying deferred restricted stock units."}],"balance_after":88425,"source":{"system":"sec-edgar","filing":"0001415889-25-000425","document":"form4-01032025_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000141588925000425/form4-01032025_040101.xml","form_type":"4"}},{"id":1691993,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2024-01-03T21:50:39.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the \"Reverse Split\"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split."},{"field":"shares","element":"transactionShares","label":"F2","text":"One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Total holdings include 33,330 shares underlying deferred restricted stock units."}],"balance_after":39042,"source":{"system":"sec-edgar","filing":"0001104659-24-000905","document":"tm241755-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465924000905/tm241755-5_4seq1.xml","form_type":"4"}},{"id":2067006,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK, PAR VALUE $0.001","published_at":"2023-01-05T02:24:18.000Z","date":"2023-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 450,000 shares underlying deferred restricted stock units."}],"balance_after":535636,"source":{"system":"sec-edgar","filing":"0001104659-23-001095","document":"tm231728-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465923001095/tm231728-2_4seq1.xml","form_type":"4"}},{"id":2287835,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:22:47.000Z","date":"2022-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"One-third of the shares will vest on each of January 1, 2023, 2024, and 2025, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The total holdings include 400,000 shares underlying deferred restricted stock units."}],"balance_after":485636,"source":{"system":"sec-edgar","filing":"0001104659-22-053616","document":"tm2213913-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053616/tm2213913-7_4seq1.xml","form_type":"4"}},{"id":2287834,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:22:47.000Z","date":"2021-11-16","kind":"other","acquired":true,"shares":230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were issued upon the consummation of Journey Medical Corporation (\"Journey's\") initial public offering as a partial dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey's 8% Cumulative Convertible Class A Preferred Stock"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 350,000 shares underlying deferred restricted stock units."}],"balance_after":435636,"source":{"system":"sec-edgar","filing":"0001104659-22-053616","document":"tm2213913-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053616/tm2213913-7_4seq1.xml","form_type":"4"}},{"id":2287833,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:22:47.000Z","date":"2021-09-30","kind":"other","acquired":true,"shares":406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued as a dividend pursuant to the Dividend Payment and Exchange Agreement executed by Fortress Biotech, Inc. on March 31, 2021 in favor of the holders of Journey Medical Corporation's 8% Cumulative Convertible Class A Preferred Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 350,000 shares underlying deferred restricted stock units."}],"balance_after":435406,"source":{"system":"sec-edgar","filing":"0001104659-22-053616","document":"tm2213913-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465922053616/tm2213913-7_4seq1.xml","form_type":"4"}},{"id":2752039,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T21:22:09.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each of January 1, 2022, 2023 and 2024, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 350,000 shares underlying deferred restricted stock units."}],"balance_after":435000,"source":{"system":"sec-edgar","filing":"0001104659-21-048824","document":"tm219139d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465921048824/tm219139d2_4.xml","form_type":"4"}},{"id":3042520,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK","published_at":"2020-09-01T12:34:04.000Z","date":"2020-08-26","kind":"purchase","acquired":true,"shares":16667,"price":18,"value":300006.0,"ownership":{"direct":true},"balance_after":16667,"source":{"system":"sec-edgar","filing":"0001104659-20-101102","document":"tm2029961-2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465920101102/tm2029961-2_4.xml","form_type":"4"}},{"id":3210989,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-13T20:06:40.000Z","date":"2020-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each January 1, 2021, 2022 and 2023, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 250,000 shares underlying deferred restricted stock units."}],"balance_after":385000,"source":{"system":"sec-edgar","filing":"0001104659-20-033109","document":"tm2011481-2_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000110465920033109/tm2011481-2_form4.xml","form_type":"4"}},{"id":3556617,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-12T20:09:21.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each January 1, 2020, 2021 and 2022, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 250,000 shares underlying deferred restricted stock units."}],"balance_after":335000,"source":{"system":"sec-edgar","filing":"0001144204-19-019495","document":"tv516218_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420419019495/tv516218_4.xml","form_type":"4"}},{"id":3747718,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-30T22:30:13.000Z","date":"2018-01-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One-third of the shares will vest on each January 1, 2019, 2020 and 2021, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The total holdings include 50,000 shares underlying deferred share units that were previously reported in Table II."}],"balance_after":285000,"source":{"system":"sec-edgar","filing":"0001144204-18-062682","document":"tv495938_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000114420418062682/tv495938_4.xml","form_type":"4"}},{"id":3899822,"issuer":{"id":7024,"kind":"organization","name":"DarioHealth Corp.","symbol":"DRIO"},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T16:07:36.000Z","date":"2018-06-06","kind":"grant","acquired":true,"shares":24353,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":78033,"source":{"system":"sec-edgar","filing":"0001144204-18-033546","document":"tv496163_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294517/000114420418033546/tv496163_4.xml","form_type":"4"}},{"id":3957096,"issuer":{"id":7024,"kind":"organization","name":"DarioHealth Corp.","symbol":"DRIO"},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-25T16:12:46.000Z","date":"2018-04-23","kind":"grant","acquired":true,"shares":6653,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was awarded such securities in exchange for waiving director fees owed for the first quarter of 2018 in the amount of $10,250."}],"balance_after":53680,"source":{"system":"sec-edgar","filing":"0001144204-18-022385","document":"tv491869_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294517/000114420418022385/tv491869_4.xml","form_type":"4"}},{"id":4104080,"issuer":{"id":7024,"kind":"organization","name":"DarioHealth Corp.","symbol":"DRIO"},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-08T16:18:33.000Z","date":"2018-01-04","kind":"grant","acquired":true,"shares":6531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was awarded such securities in exchange for waiving director fees owed for the fourth quarter of 2017 in the amount of $10,250."}],"balance_after":47027,"source":{"system":"sec-edgar","filing":"0001144204-18-001312","document":"tv482701_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294517/000114420418001312/tv482701_4.xml","form_type":"4"}},{"id":4180613,"issuer":{"id":7024,"kind":"organization","name":"DarioHealth Corp.","symbol":"DRIO"},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-25T16:07:39.000Z","date":"2017-10-23","kind":"grant","acquired":true,"shares":5521,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter of 2017 in the amount of $10,250."}],"balance_after":40496,"source":{"system":"sec-edgar","filing":"0001144204-17-054097","document":"tv477609_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294517/000114420417054097/tv477609_4.xml","form_type":"4"}},{"id":4253217,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2017-07-21T20:11:46.000Z","date":"2017-03-10","kind":"grant","acquired":true,"shares":16666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon\nthe vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the \"Plan\"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set\nforth in the Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs.\nPage"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon\nthe vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the \"Plan\"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set\nforth in the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon\nthe vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the \"Plan\"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set\nforth in the Plan."}],"balance_after":49998,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":16666},"source":{"system":"sec-edgar","filing":"0001638599-17-000720","document":"doc4_4609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000163859917000720/doc4_4609.xml","form_type":"4"}},{"id":4258989,"issuer":{"id":7024,"kind":"organization","name":"DarioHealth Corp.","symbol":"DRIO"},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-11T16:06:57.000Z","date":"2017-07-10","kind":"grant","acquired":true,"shares":4433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was awarded such securities in exchange for waiving director fees owed for the second quarter of 2017 in the amount of $10,250."}],"balance_after":34975,"source":{"system":"sec-edgar","filing":"0001144204-17-036438","document":"v470578_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294517/000114420417036438/v470578_4.xml","form_type":"4"}},{"id":4351462,"issuer":{"id":7024,"kind":"organization","name":"DarioHealth Corp.","symbol":"DRIO"},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-17T16:25:04.000Z","date":"2017-04-13","kind":"grant","acquired":true,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was awarded such securities in exchange for waiving director fees owed for the first quarter of 2017 in the amount of $10,250."}],"balance_after":30542,"source":{"system":"sec-edgar","filing":"0001144204-17-020721","document":"v464370_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294517/000114420417020721/v464370_4.xml","form_type":"4"}},{"id":4473371,"issuer":{"id":7024,"kind":"organization","name":"DarioHealth Corp.","symbol":"DRIO"},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-02-01T16:06:27.000Z","date":"2017-01-30","kind":"grant","acquired":true,"shares":16007,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal quarterly installments commencing on January 30, 2017."}],"balance_after":16007,"derivative":{"exercise_price":3.202,"expiration_date":"2023-01-30","underlying":"Common Stock","underlying_shares":16007},"source":{"system":"sec-edgar","filing":"0001144204-17-005356","document":"v457882_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294517/000114420417005356/v457882_4.xml","form_type":"4"}},{"id":4482951,"issuer":{"id":6822,"kind":"organization","name":"Fortress Biotech, Inc."},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2017-01-24T23:56:55.000Z","date":"2017-01-01","kind":"grant","acquired":true,"shares":16666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the \"Plan\"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the \"Plan\"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the \"Plan\"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan."}],"balance_after":33332,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":16666},"source":{"system":"sec-edgar","filing":"0001638599-17-000106","document":"doc4_4430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1429260/000163859917000106/doc4_4430.xml","form_type":"4"}},{"id":4491163,"issuer":{"id":7024,"kind":"organization","name":"DarioHealth Corp.","symbol":"DRIO"},"owners":[{"id":70287,"kind":"person","name":"Hoenlein Malcolm","position":1,"cik":"0001294517","reported_name":"Hoenlein Malcolm","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-13T16:46:43.000Z","date":"2017-01-12","kind":"grant","acquired":true,"shares":6388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was awarded such securities in exchange for waiving director fees owed for the third quarter and fourth quarter of 2016 in the amount of $20,500."}],"balance_after":27742,"source":{"system":"sec-edgar","filing":"0001144204-17-002219","document":"v456903_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1294517/000114420417002219/v456903_4.xml","form_type":"4"}}]}